Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: reduction of erythropoietin dose in 4 years of follow-up

BACKGROUND: Ferric carboxymaltose (FCM) is a parenteral, dextran-free iron formulation designed to overcome the limitations of existing iron preparations. The main aim of this study was to retrospectively examine results obtained from a long period of FCM therapy in hemodialysis patients who have be...

Descripción completa

Detalles Bibliográficos
Autores principales: Lacquaniti, Antonio, Pasqualetti, Patrizio, Tocco, Teresa Casuscelli di, Campo, Susanna, Rovito, Stefania, Bucca, Maurizio, Ragusa, Antonino, Monardo, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Nephrology 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7530360/
https://www.ncbi.nlm.nih.gov/pubmed/32839355
http://dx.doi.org/10.23876/j.krcp.20.015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7530360/
https://www.ncbi.nlm.nih.gov/pubmed/32839355
http://dx.doi.org/10.23876/j.krcp.20.015

Ejemplares similares